Axisresearch
List of Categories
- Aerospace & Defense
- Agriculture
- Animal Nutrition & Wellness
- Automation
- Automotive
- Chemical & Materials
- Consumer Goods and Services
- Electronics
- Energy & Mining
- Financial Services & Investment Intelligence
- Food & Beverage
- Healthcare
- Heavy Industry
- Home & Property Improvement
- Information & Communications Technology
- Investment Opportunities
- Manufacturing
- NEO
- Others
- Packaging
- Retail
- Technology & Media
- Transportation & Logistics
Sorted by Name
Publishers
Countries
Urology Devices Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 118 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 118 pages
- Published: 07-06-2019
Market Overview
The global urology devices market was valued at USD 30,967.15 million in 2018, and is estimated to be valued at USD 44,804.97 million in 2024, witnessing a CAGR of 6.35%. The key factors propelling the market growth include high incidence of urologic conditions, rising geriatric population, and technological advancements.
According to the American Urological Association Foundation (AUAF), benign prostatic hyperplasia (BPH), urinary incontinence (UI), urinary tract infections (UTIS), and kidney and ureteral stones are among the most common urological diseases. According to the United States Department of Health and Human Services, the overall prevalence of CKD among the American population is about 14%, and almost half of the individuals with CKD suffer from diabetes and/or cardiovascular diseases. Annually, more than 661,000 Americans suffer from kidney failure, and 468,000 patients are given dialysis. Urinary tract infections (UTIs) are one of the most common microbial diseases affecting people of all age groups. Globally, UTIs affect around 150 million people every year. Diabetic patients have a higher risk of developing UTIs and complications associated with it. With a global increase in diabetic population, complications, like dysuria and organ damage that are associated with UTIs, are also on the rise.
With high incidence rates and health complications associated with urological diseases, there is an increasing demand for healthcare interventions to manage them, which, in turn, is propelling the market of urology surgical and diagnostic devices.
Scope of the Report
This report estimates the global urology devices market (henceforth, referred to as the market studied). It includes a detailed analysis of urological devices, consumables, and accessories, along with the areas in which they are being used and their end users.
Urological conditions include kidney stone disease (urolithiasis), incontinence in men and women, benign prostate hyperplasia (BPH, noncancerous swelling of prostate occurring in men with increasing age, prostate cancer, and erectile dysfunction in men, etc.
Key Market Trends
Kidney Disease is Expected to hold its Highest Market Share in the Disease Segment
In the disease segment of the urology devices market, kidney disease is believed to have the largest market size and is expected to witness a CAGR of 6.47% during the forecast period.
The various kidney diseases include renal cyst, cystic kidney diseases, chronic kidney disease, hemolytic-uremic syndrome, and lupus nephrite, among others. Most of the kidney diseases lead to kidney failure, which requires early diagnosis for prompt treatment.
According to the statistics by the National Kidney Foundation, in 2015, it was estimated that chronic kidney diseases affected approximately 10% of the world’s population. However, most of this population remain undiagnosed in the early stages, eventually leading to death, worldwide. According to the Global Burden of Disease study, in 2010, chronic kidney disease ranked 18th as the cause for the total number of deaths, worldwide.
An increase in awareness, along with support from the government through reimbursement, and innovation in products, in order to develop low-cost and effective treatment, are some elements that are expected to drive the market, over the forecast period. The highest growth rate is seen in the Asia-Pacific countries that are contributed by India and China, due to the increasing patient pool, availability of local low-cost products, and rapid adoption of urology devices.
North America Dominates the Market and is Expected to do the Same in the Forecast Period
North America currently dominates the market for urology devices and is expected to continue its stronghold for a few more years. Benign prostatic hyperplasia (BPH) is among the most untapped segments in the urology market, with several US-based companies working on upgrading their devices in this segment, either by collaboration or acquisition. Recently, in 2018, Boston Scientific Corporation acquired NxThera and its RezÅ«m benign prostatic hyperplasia device. Additionally, several ventures partners, as well as other investors have funded significantly for minimally invasive devices for the treatment of urology diseases. For instance, Zenflow received USD 31.4 million funding, while UroCure, a medical device startup raised USD 2.5 million for urethral slings, in 2018. The technology was acquired by Endo International’s subsidiary, American Medical Systems Holdings.
Thus, over the forecast period, technological advancements, a high percentage of urology cases in hospitals, and increasing funding are expected to be the major drivers for the growth of the urology devices market.
Competitive Landscape
The urology devices market is highly competitive and consists of several major players. With increasing technological advancements and product innovations, mid-size to smaller companies are expected to increase their market presence by introducing new devices with lesser prices. Companies, like Baxter, Boston Scientific, C. R. Bard, Medtronic, and Siemens, hold the substantial share in the market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 High Incidence of Urologic Conditions
4.2.2 Rising Geriatric Population
4.2.3 Technological Advancements
4.3 Market Restraints
4.3.1 Stringent Regulatory Policies for Validation of Medical Devices
4.3.2 High Cost of Urology Devices
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product
5.1.1 Instruments
5.1.1.1 Dialysis Devices
5.1.1.2 Endoscopes and Endovision Systems
5.1.1.3 Lasers and Lithotripsy Devices
5.1.1.4 Robotic Systems
5.1.1.5 Peripheral Instruments
5.1.1.6 Urodynamic Systems
5.1.2 By Consumables and Accessories
5.1.2.1 Dialysis Consumables
5.1.2.2 Guidewires
5.1.2.3 Surgical Dissectors, Forceps, and Needle Holders
5.1.2.4 Retrieval Devices and Extractors
5.1.2.5 Catheters
5.1.2.6 Stents
5.1.2.7 Biopsy Devices
5.1.2.8 Tubes and Distal Attachments
5.1.2.9 Dilator Sets and Urethral Access Sheaths
5.1.2.10 Drainage Bags
5.1.2.11 Other Consumables and Accessories
5.2 By Disease
5.2.1 Kidney Diseases
5.2.2 Urological Cancer and BPH
5.2.3 Pelvic Organ Prolapse
5.2.4 Other Diseases
5.3 By End User
5.3.1 Hospitals and Clinics
5.3.2 Dialysis Centers
5.3.3 Other End Users
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Baxter International Inc.
6.1.2 Boston Scientific Corporation
6.1.3 C. R. Bard Inc.
6.1.4 Cook Medical Incorporated
6.1.5 Dornier MedTech GmbH
6.1.6 Fresenius Medical Care AG & Co. KGaA
6.1.7 Intuitive Surgical Inc.
6.1.8 Karl Storz SE & Co. KG
6.1.9 Medtronic PLC
6.1.10 Olympus Corporation
6.1.11 Richard Wolf GmbH
6.1.12 Siemens Healthcare GmbH
6.1.13 Stryker Corporation
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Product
Instruments
Dialysis Devices
Endoscopes and Endovision Systems
Lasers and Lithotripsy Devices
Robotic Systems
Peripheral Instruments
Urodynamic Systems
By Consumables and Accessories
Dialysis Consumables
Guidewires
Surgical Dissectors, Forceps, and Needle Holders
Retrieval Devices and Extractors
Catheters
Stents
Biopsy Devices
Tubes and Distal Attachments
Dilator Sets and Urethral Access Sheaths
Drainage Bags
Other Consumables and Accessories
By Disease
Kidney Diseases
Urological Cancer and BPH
Pelvic Organ Prolapse
Other Diseases
By End User
Hospitals and Clinics
Dialysis Centers
Other End Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Ambulatory EHR Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 118 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 118 pages
- Published: 07-06-2019
Market Overview
The factors propelling the growth of the ambulatory EHR market include the rising adoption of EHR solutions in developed markets, increasing need for fluid movement of healthcare information and technological advancements, and government initiatives to maintain and enhance patient health record portals.
In the past decade, it was observed that paper-based records were being phased out at a rapid pace, with digitization and virtualization creating multiple growth opportunities for the better management of patient records across the chain of hospitals and research centers in healthcare. Thus, there has been increasing adoption by multiple healthcare centers across developed markets, which was found to be one of the major drivers of the market studied.
The use of ambulatory EHR has been beneficial across several developed markets in Europe, East Asia, and North America, in the recent years. Some countries in Europe and Asia-Pacific, such as Demark, England, Finland, the Netherlands, and New Zealand, have consistently shown high usage of ambulatory EHR.
There are also increasing investments being made by governments to maintain and enhance patient health record portals. The federal government in the United States has made several investments to transform the US healthcare industry into the electronic age.
Scope of the Report
As per the scope of the report, ambulatory care involves patients who do not stay overnight for disease treatment in any healthcare setting. EHR is a patient’s record that helps authorized users to securely access the available information about the patient. The information on EHR can be shared across different healthcare settings through network connected systems, which allows physicians to take better decisions and provide improved coordinated care for patients. The EHR developed for ambulatory services are simpler than inpatient EHRs, as they deal with a single practice and its patients, and are used in outpatient care facilities and smaller practices.
Key Market Trends
Cloud-based Solutions Segment, By Delivery Mode, is Expected to Grow the Fastest
The cloud-based solutions sub-segment is expected to occupy a high share, due to its cost-effective services and advantages of user-friendly software models. Patient information is stored and managed using these cloud-based electronic health records, making them more secure. It also allows physicians and medical practitioners to control access to sensitive information.
On-premise storage has also evolved over the past several years. These systems require the installation of specific hardware and software. Therefore, cloud-based solutions are the most commonly adopted solutions, since these are much cheaper when compared to on-premise solutions.
Asia-Pacific holds the Fastest Growth and is Expected to Follow the Same Trend over the Forecast Period
Asia-Pacific is expected to be the fastest-growing region, due to high investments by governments, non-profit entities, and the private sector, in EHR systems. The factors responsible for the growth include the growing ageing population and rising incidence of chronic diseases in various countries, such as India and China. In addition, the region has a better hospital network and training programs that increase the presence of general practitioners, and an increase in ambulatory care services.
Competitive Landscape
Most of the companies present in the market are efficient at the technological front, but require significant support for enhancing their services and expanding their businesses. Thus, mergers and acquisitions offer significant opportunities to gain the attention of a large number of providers and hospitals across developed regions.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Adoption of EHR Solutions in Developed Markets
4.2.2 Increasing Need for Fluid Movement of Healthcare Information and Technological Advancements
4.2.3 Government Initiatives to Maintain and Enhance Patient Health Record Portals
4.3 Market Restraints
4.3.1 Inconsistent EHR Adoption across Emerging Markets
4.3.2 Regulatory Barriers
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Application
5.1.1 Practice Management
5.1.2 Patient Management
5.1.2.1 Interventional/Surgical Simulators
5.1.3 E-prescribing
5.1.4 Referral Management
5.1.5 Population Health Management
5.1.6 Other Applications
5.2 By Delivery Mode
5.2.1 Cloud-based Solutions
5.2.2 On-premise Solutions
5.3 By Practice Size
5.3.1 Large Practices
5.3.2 Medium-sized Practices
5.3.3 Small Practices
5.4 By End User
5.4.1 Hospital-owned Ambulatory Centers
5.4.2 Independent Ambulatory Centers
5.5 Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East & Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East & Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Allscripts Healthcare Solutions Inc.
6.1.2 Aprima Medical Software Inc.
6.1.3 Athenahealth Inc.
6.1.4 Cerner Corporation
6.1.5 eClinicalWorks
6.1.6 Epic Systems Corporation
6.1.7 Greenway Health
6.1.8 Medhost
6.1.9 Medical Information Technology Inc.
6.1.10 Nextgen Healthcare Information Systems LLC
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Application
Practice Management
Patient Management
Interventional/Surgical Simulators
E-prescribing
Referral Management
Population Health Management
Other Applications
By Delivery Mode
Cloud-based Solutions
On-premise Solutions
By Practice Size
Large Practices
Medium-sized Practices
Small Practices
By End User
Hospital-owned Ambulatory Centers
Independent Ambulatory Centers
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Platelet Rich Plasma Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 114 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 114 pages
- Published: 07-06-2019
Market Overview
The global platelet-rich plasma market is expected to register a CAGR of approximately 14% over the forecast period. The key factors that are augmenting the growth of the market include rising incidences of sports injuries, increasing number of androgenic alopecia patients, growing use of platelet-rich plasma in various therapeutic areas, and rise in the prevalence of arthritis.
Osteoarthritis (OA) is the most common form of chronic disorder of the joints, and it has some detrimental effects on the quality of life of the patients. Progressive cartilage destruction, osteophyte formation, and subchondral sclerosis are characteristic to osteoarthritis. Platelet-rich plasma (PRP) is an autologous concentration of a high number of platelets in a small volume of plasma. PRP is prepared to centrifuge blood. In knee OA, PRP injections target to promote cartilage repair in order to relieve symptoms of osteoarthritis, hence delaying the need for joint replacement surgery.
The rising prevalence of the arthritis is augmenting the demand of the blood products, which is ultimately helping the growth of the platelet-rich plasma market.
Scope of the Report
As per the scope of the report, platelet-rich plasma (PRP) prolotherapy, like dextrose prolotherapy, is a method of injection designed to stimulate healing. Platelet-rich plasma is defined as autologous blood with concentrations of platelets above baseline levels, which contains at least seven growth factors.
Key Market Trends
Pure PRP Segment by Type is Expected to Hold the Largest Market Share
The pure PRP segment of the global platelet rich plasma market is believed to have the largest market share.
The prime factor responsible for the growth of this segment is the significance of this type of platelet plasma for the person. Pure PRP has an edge over traditional PRP, as it requires a two-step concentration process that helps in eliminating unwanted red blood cells (RBCs) and neutrophils. RBCs (that have no therapeutic effects for regeneration) can create a more viscous solution that can be more painful when injected. Neutrophils, a type of white blood cell, have inflammatory components that may increase pain and inflammation post-treatment.
Pure PRP helps the stem cells and regenerative cells in the repair and in rebuilding the damaged tissue. This ultimately speeds up the healing process and reduces pain. In addition, it promotes increased strength and improves the overall function. Therefore, owing to the contribution of pure PRP in the healing process and the rising use of it as a blood product, the segment is expected to dominate the market in the coming future.
North America Dominates the Market and is Expected to Continue the Same Trend for Next Few Years
North America currently dominates the platelet-rich plasma market and is expected to continue its stronghold for a few more years. The United States is a major market, and this is mainly due to the US government’s initiatives to develop blood products. In addition, the emergence and adoption of novel technologies are going to help the market in a positive manner.
Competitive Landscape
Companies, such as Biotest AG, China Biologic Products Inc., CSL Ltd, Octapharma AG, and LFB SA, are some of the key players operating in the global platelet-rich plasma market. With the advancement in technology, new players are expected to come in the market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Incidences of Sports Injuries
4.2.2 Increasing Number of Androgenic Alopecia Patients
4.2.3 Growing Use of Platelet-rich Plasma in Various Therapeutic Areas
4.2.4 Rising Prevalence of Arthritis
4.3 Market Restraints
4.3.1 Stringent Regulatory Policies
4.3.2 High Prices of Plasma Therapy
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Type
5.1.1 Pure PRP
5.1.2 Leukocyte-rich PRP
5.1.3 Pure Platelet-rich Fibrin
5.1.4 Leukocyte-rich Fibrin
5.2 By Source
5.2.1 Autologous
5.2.2 Allogenic
5.3 By Application
5.3.1 Orthopedic
5.3.1.1 Arthritis
5.3.1.2 Chronic Tendinitis
5.3.1.3 Bone Repair and Regeneration
5.3.2 Dermatology
5.3.2.1 Androgenic Alopecia
5.3.2.2 Plastic Surgery
5.3.2.3 Cardiac Muscle Injury
5.3.2.4 Dental
5.3.2.5 Nerve Injury
5.3.2.6 Other Applications
5.3.3 By End User
5.3.3.1 Hospitals and Clinics
5.3.3.2 Research Institutes
5.3.3.3 Other End Users
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bio Product Laboratory Ltd (BPL)
6.1.2 Biolife Plasma Services
6.1.3 Biotest AG
6.1.4 Cambryn Biologics LLC
6.1.5 China Biologic Products Inc.
6.1.6 CSL Ltd
6.1.7 Grifols International SA
6.1.8 Kedrion SpA
6.1.9 LFB SA
6.1.10 Octapharma AG
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Type
Pure PRP
Leukocyte-rich PRP
Pure Platelet-rich Fibrin
Leukocyte-rich Fibrin
By Source
Autologous
Allogenic
By Application
Orthopedic
Arthritis
Chronic Tendinitis
Bone Repair and Regeneration
Dermatology
Androgenic Alopecia
Plastic Surgery
Cardiac Muscle Injury
Dental
Nerve Injury
Other Applications
By End User
Hospitals and Clinics
Research Institutes
Other End Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
In-Vitro Diagnostic Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 115 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 115 pages
- Published: 07-06-2019
Market Overview
Global In-Vitro Diagnostic market was valued at USD 59,272.87 million in 2018 and is estimated to be valued at USD 82,626.27 million in 2024, witnessing a CAGR of 4.81%. The growth of the global IVD market can be attributed to the high prevalence of chronic and infectious diseases. Chronic diseases are a growing global challenge, and according to WHO estimates, account for approximately 60% of all deaths, worldwide. The current market is also growing due to the use of advanced technologies in the IVD market. There has been a paradigm shift from traditional diagnostics to a new generation diagnostics of that works at the gene level. This was made possible by the inclusion of advanced technologies, such as genetic testing, molecular diagnostics, polymerase chain reaction (PCR) and next-generation sequencing (NGS).
Scope of the Report
As per the scope of this report, in vitro diagnostics involves medical devices and consumables that are utilized to perform in vitro tests on various biological samples. They are used for the diagnosis of various medical conditions, such as chronic diseases.
Key Market Trends
Reagent is Expected to hold its Highest Market Share in the Product Segment
In the product segment of the In-Vitro Diagnostic market, the reagent is believed to have the largest market size and is expected to witness a CAGR of 4.8% in the forecast period.
The reagent segment of the market studied includes chemical, biological, or immunological components, solutions, or preparations intended by the manufacturer to be used during the in-vitro diagnosis process. Given the high cost of many diagnostic platforms, it is common for manufacturers to lease equipment instead of selling technology outright to end users. In these arrangements, the lease is tied to contracts to purchase associated reagents or assays for the equipment over the life of the contract. Many diagnostic companies have in excess of 75% of sales from consumables such as assays and reagents, and such agreements guarantee the generation of cyclic revenues associated with the sale of reagents and other consumables.
Many developing countries have established local immunoassay reagent programs to manufacture low-cost, high-quality immunoassay reagents. Kits from these projects are now beginning to become available and are likely to fuel the market expansion.
North America Dominates the Market and is Expected to continue its Dominance in the Forecast Period
North America currently dominates the market for In-Vitro Diagnostic and is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future owing to the well-established healthcare industry and rising prevalence of the chronic diseases in the region. The United States holds the majority of the market in the North America region; this is due to the rising healthcare expenditure, along with rapid adoption of point-of-care testing.
Competitive Landscape
The In-Vitro Diagnostic market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancement and product innovation, mid-size to smaller companies are increasing their market presence by introducing new products at lesser prices. Companies like Thermo Fischer Scientific Inc., Qiagen N.V., Bio-Rad Laboratories, Inc., Siemens Healthcare GmbH and F. Hoffmann-La Roche AG. holds the substantial market share in the In-Vitro Diagnostic market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 High Prevalence of Chronic Diseases
4.2.2 Increasing Use of Point-of-care (POC) Diagnostics
4.2.3 Advanced Technologies
4.2.4 Increasing Awareness and Acceptance of Personalized Medicine and Companion Diagnostics
4.3 Market Restraints
4.3.1 Stringent Regulations
4.3.2 Cumbersome Reimbursement Procedures
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Technique
5.1.1 Histochemistry
5.1.2 Molecular Diagnostics
5.1.3 Hematology
5.1.4 POC Testing
5.1.5 Self-blood Glucose Testing
5.1.6 Immunochemistry
5.1.7 Other Techniques
5.2 By Product
5.2.1 Instrument
5.2.2 Reagent
5.2.3 Others
5.3 By Usability
5.3.1 Disposable IVD Devices
5.3.2 Reusable IVD Devices
5.4 By Application
5.4.1 Infectious Disease
5.4.2 Diabetes
5.4.3 Cancer/Oncology
5.4.4 Cardiology
5.4.5 Autoimmune Disease
5.4.6 Nephrology
5.4.7 Drug Testing
5.4.8 Other Applications
5.5 By End Users
5.5.1 Academia
5.5.2 Laboratories
5.5.3 Hospitals & Clinics
5.5.4 Other End Users
5.6 Geography
5.6.1 North America
5.6.1.1 US
5.6.1.2 Canada
5.6.1.3 Mexico
5.6.2 Europe
5.6.2.1 Germany
5.6.2.2 UK
5.6.2.3 France
5.6.2.4 Italy
5.6.2.5 Spain
5.6.2.6 Rest of Europe
5.6.3 Asia Pacific
5.6.3.1 China
5.6.3.2 Japan
5.6.3.3 India
5.6.3.4 Australia
5.6.3.5 South Korea
5.6.3.6 Rest of Asia-Pacific
5.6.4 Middle East and Africa
5.6.4.1 GCC
5.6.4.2 South Africa
5.6.4.3 Rest of Middle East and Africa
5.6.5 South America
5.6.5.1 Brazil
5.6.5.2 Argentina
5.6.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 BioMérieux
6.1.2 Danaher Corporation
6.1.3 F. Hoffmann-La Roche AG
6.1.4 Becton, Dickinson and Company
6.1.5 Bio-Rad Laboratories, Inc.
6.1.6 Abbott Laboratories
6.1.7 Arkray Inc.
6.1.8 Sysmex Corporation
6.1.9 Ortho Clinical Diagnostics
6.1.10 Siemens Healthcare GmbH
6.1.11 Thermo Fischer Scientific Inc.
6.1.12 QIAGEN N.V.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Technique
Histochemistry
Molecular Diagnostics
Hematology
POC Testing
Self-blood Glucose Testing
Immunochemistry
Other Techniques
By Product
Instrument
Reagent
Others
By Usability
Disposable IVD Devices
Reusable IVD Devices
By Application
Infectious Disease
Diabetes
Cancer/Oncology
Cardiology
Autoimmune Disease
Nephrology
Drug Testing
Other Applications
By End Users
Academia
Laboratories
Hospitals & Clinics
Other End Users
Geography
North America
US
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Medical Coding Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 115 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 115 pages
- Published: 07-06-2019
Market Overview
The major factors found propelling the growth of the market include the escalating demand for coding services, rising need for a universal language to reduce frauds and misinterpretations associated with insurance claims, and high demand to streamline hospital billing procedures.
There is a high demand for medical billers and coders in the current job market. Thus, coding-related jobs are expanding, due to the growing landscape of the business side of healthcare, along with their efficiency to automate large amounts of work. Hence, the escalating demand for coding jobs is likely to drive the market studied across the world.
The technological advancements in the healthcare industry and constantly changing classification systems are expected to create potential revenue opportunities for players operating in the target market over the forecast period.
In addition, data security is a major concern for healthcare organizations, and offshore coding companies are also becoming aware of these data security concerns, while understanding that breach in a client’s data is likely to result in the loss of business. Thus, leading offshore coding firms are building a secure environment for the coders to work in.
Scope of the Report
As per the scope of the report, medical coding is the transformation of healthcare diagnosis, procedures, medical services, and equipment into universal medical alphanumeric codes. Medical coding is thus being increasingly used in the present scenario, to create a proper record of patient care, streamline the medical billing process, accelerate payments to physicians, and identify the healthcare areas that require focus.
Key Market Trends
International Classification of Diseases (ICD) is the Largest Segment by Classification System that is Expected to Grow During the Forecast Period
The international classification of diseases (ICD) segment is expected to register a significant share, in terms of revenue, over the forecast period, owing to the increasing demand for trained medical coders. The need for ICD is increasing across the world, owing to a growing prevalence of diseases. Hence this segment is expected to grow in the future, due to the rising growth of medical coding across the world.
North America Reported the Largest Growth and is Expected to Follow the Same Trend Over the Forecast Period
The North American market is estimated to hold the largest share, in terms of revenue, over the forecast period, owing to technological advancements and improved healthcare infrastructure in various countries in this region. Therefore, the high demand for specialist coders and the presence of a favorable healthcare system are the key factors that are anticipated to drive the market growth.
Competitive Landscape
The number of professional coders is expected to rise significantly during the forecast period, thus boosting the number of companies providing platforms for medical coding professionals. Thus, the market seems to be highly fragmented, due to the presence of many local providers offering a wide array of services.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Escalating Demand for Coding Services
4.2.2 Rising Need for a Universal Language to Reduce Frauds and Misinterpretations Associated with Insurance Claims
4.2.3 High Demand to Streamline Hospital Billing Procedures
4.3 Market Restraints
4.3.1 Changing Regulations Related to Medical Coding
4.3.2 Data Security Concerns
4.3.3 Lack of Adequately Equipped IT Professionals
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Classification System
5.1.1 International Classification of Diseases (ICD)
5.1.2 Healthcare Common Procedure Code System (HCPCS)
5.2 By Component
5.2.1 In-house
5.2.2 Outsourced
5.3 By End User
5.3.1 Hospitals
5.3.2 Diagnostic Centers
5.3.3 Other End Users
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 3M Company
6.1.2 Aviacode Inc.
6.1.3 Dolbey Systems Inc.
6.1.4 Maxim Health Information Services
6.1.5 Medical Record Associates LLC
6.1.6 Nuance Communications Inc.
6.1.7 Optum Inc.
6.1.8 Oracle Corporation
6.1.9 Parexel International Corporation
6.1.10 Precyse Solutions LLC
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Classification System
International Classification of Diseases (ICD)
Healthcare Common Procedure Code System (HCPCS)
By Component
In-house
Outsourced
By End User
Hospitals
Diagnostic Centers
Other End Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Protein Engineering Market- Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 114 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 114 pages
- Published: 07-06-2019
Market Overview
The propelling factors for the growth of the global protein engineering market include the increasing prevalence of protein deficient diseases, increase in adoption of protein drugs over non-protein drugs, increased demand for alternatives to chemical processes, and rising government funding for protein engineering.
Protein-energy malnutrition (PEM) is increasing in the rural areas of emerging economies. It refers to a group of disorders that includes marasmus, kwashiorkor and intermediate states of marasmus-kwashiorkor. Therefore the prevalence of kwashiorkor varies from geography to geography. It is rare in the United States; however most affected regions include Southeast Asia, Central America, Congo, Puerto Rico, Jamaica, and South Africa. Thus, the increasing prevalence of protein-deficient diseases is driving the overall market.
There is a rising number of government initiatives, such as funding R&D for protein engineering and awareness programs, which have influenced the healthcare industry. The government is thus proactively investing in many of the research studies. For instance, Protein Technologies Ltd (PTL) has received funding from the UK government’s Technology Strategy Board (now Innovate UK) for its innovative research in protein engineering. Hence the increasing number of government initiatives for the efficient protein engineering research helps in driving the overall growth of the market.
Protein engineering also holds immense opportunity in the agrochemical industry as engineering in proteins may lead to the generation of enzymes with improved function that may increase the crop yield or facilitate the biofuel production. It is also likely to play an important role as a tool to attain increased crop yield needed to meet future demands.
Scope of the Report
As per the scope of the report, protein engineering is the manipulation of the structures of proteins to produce the desired properties, or the synthesis of proteins with particular structures. It is the process by which novel proteins with desired properties are developed, and has grown enormously since past three decades. In the past years, protein engineers have successfully generated a wide range of proteins tailored to specific health, industry, medicine, research, and biotechnology applications.
Key Market Trends
Monoclonal Antibodies by Protein Type is the Largest Segment that is Expected to Grow Fastest During the Forecast Period
Monoclonal antibodies are anticipated to hold the largest market share in the future, owing to their high adoption for numerous therapies, such as cancer and autoimmune diseases. They also have tremendous applications in the fields of therapeutics, diagnostics, and targeted drug delivery systems, for infectious diseases caused by viruses, bacteria, and protozoa, as well as for cancer, and metabolic and hormonal disorders. Hence, recombinant deoxyribonucleic acid technology through genetic engineering has successfully led to the possibility of reconstruction of monoclonal antibodies, thus fueling the growth of the segment.
Asia-Pacific Holds the Fastest Growth and is Expected to Follow the Same Trend Over the Forecast Period
The Asia-Pacific market is expected to witness the fastest CAGR during the forecast period, owing to the growing presence of contract research organizations, rising healthcare IT spending, and unprecedented evolution of the healthcare infrastructure and standards across this region. Growing demand for personalized medicine and strong R&D investments in proteomics-based drug discovery projects are also supplementing the growth of the protein engineering market.
Competitive Landscape
The global protein engineering market players are highly focused on strategies, such as mergers and acquisitions, new product development initiatives, and geographical expansion. As the cost of R&D is high and requires high-end infrastructure, most of the pharmaceutical and biotechnology companies are moving toward CROs. Most of the players in the CRO industry are joining forces in order to create a market position.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Protein-deficient Diseases
4.2.2 Increased Demand for Alternatives to Chemical Processes
4.2.3 Increase in Adoption of Protein Drugs over Non-protein Drugs
4.2.4 Rising Government Funding for Protein Engineering
4.3 Market Restraints
4.3.1 Lack of Experts to Strategize the Process
4.3.2 High Costs
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product Type
5.1.1 Modified Enzymes
5.1.2 Insulin
5.1.3 Monoclonal Antibodies
5.1.4 Coagulation Factors (Blood factors + Tissue plasminogen)
5.1.5 Vaccines
5.1.6 Growth Factors (Hormones + Cytokine)
5.1.7 Other Product Types
5.2 By Technology
5.2.1 Irrational Protein Design
5.2.2 Rational Protein Design
5.3 By End User
5.3.1 Pharmaceutical and Biotechnology Companies
5.3.2 Academic Institutions
5.3.3 Contract Research Organizations (CROs)
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Agilent Technologies Inc.
6.1.2 Amgen Inc.
6.1.3 Bruker Corporation
6.1.4 Bio-Rad Laboratories Inc.
6.1.5 Eli Lilly and Company
6.1.6 Merck KGaA
6.1.7 Novo Nordisk AS
6.1.8 PerkinElmer Inc.
6.1.9 Thermo Fisher Scientific Inc.
6.1.10 Waters Corporation
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Product Type
Modified Enzymes
Insulin
Monoclonal Antibodies
Coagulation Factors (Blood factors + Tissue plasminogen)
Vaccines
Growth Factors (Hormones + Cytokine)
Other Product Types
By Technology
Irrational Protein Design
Rational Protein Design
By End User
Pharmaceutical and Biotechnology Companies
Academic Institutions
Contract Research Organizations (CROs)
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America